Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
931.61
+4.55 (0.49%)
Apr 7, 2026, 12:50 PM EDT - Market open
Eli Lilly Revenue
In the year 2025, Eli Lilly had annual revenue of $65.18B with 44.70% growth. Eli Lilly had revenue of $19.29B in the quarter ending December 31, 2025, with 42.55% growth.
Revenue (ttm)
$65.18B
Revenue Growth
+44.70%
P/S Ratio
12.46
Revenue / Employee
$1,303,580
Employees
50,000
Market Cap
833.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.18B | 20.14B | 44.70% |
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
| Dec 31, 2018 | 21.49B | 1.52B | 7.61% |
| Dec 31, 2017 | 19.97B | -1.25B | -5.88% |
| Dec 31, 2016 | 21.22B | 1.26B | 6.33% |
| Dec 31, 2015 | 19.96B | 343.10M | 1.75% |
| Dec 31, 2014 | 19.62B | -3.50B | -15.13% |
| Dec 31, 2013 | 23.11B | 509.70M | 2.25% |
| Dec 31, 2012 | 22.60B | -1.68B | -6.93% |
| Dec 31, 2011 | 24.29B | 1.21B | 5.25% |
| Dec 31, 2010 | 23.08B | 1.24B | 5.68% |
| Dec 31, 2009 | 21.84B | 1.46B | 7.19% |
| Dec 31, 2008 | 20.37B | 1.74B | 9.33% |
| Dec 31, 2007 | 18.63B | 2.94B | 18.75% |
| Dec 31, 2006 | 15.69B | 1.05B | 7.14% |
| Dec 31, 2005 | 14.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
LLY News
- 4 days ago - India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation - Reuters
- 4 days ago - A new weight-loss pill is here, and it could reshape the GLP-1 market - Fast Company
- 5 days ago - Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs - CNBC
- 5 days ago - Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh - Benzinga
- 5 days ago - Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison - CNBC
- 5 days ago - Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead - Reuters
- 5 days ago - Pricing and availability of Novo, Lilly's weight-loss drugs - Reuters
- 5 days ago - Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Reuters